SciSparc Ltd. (SPRC) company profile

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on creating and developing technologies and therapeutic assets based on cannabinoid treatments. Through its majority-owned subsidiary, NeuroThera Labs Inc., the company advances clinical programs utilizing Δ9-tetrahydrocannabinol and non-psychoactive cannabidiol to address central nervous system conditions. Its development pipeline includes SCI-110 for Tourette syndrome, Alzheimer’s disease, and agitation, as well as SCI-210 for autism spectrum disorder and status epilepticus. In addition, the company oversees early commercial initiatives for CannAmide, an oral palmitoylethanolamide tablet formulation intended for Canadian retail pharmacies, alongside an eCommerce subsidiary marketing hemp seed oil products on Amazon Marketplace.

The company operates primarily out of Israel, where it conducts its core research and development activities and corporate functions. Additional development operations, public listings, and sales channels run through Canadian corporate entities and global third-party online retail platforms. SciSparc maintains its executive headquarters and primary corporate offices in Tel Aviv, Israel.

Summary of the business section of SciSparc's latest annual report, written by StockData.

“333-214458 2,000,000 American Depositary Shares Each Representing Forty Ordinary Shares We are offering 2,000,000 American Depositary Shares, or ADSs, at the public offering price of $6.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“On December 31, 2023, we had 3 full-time employees.”